Chromocell Therapeutics (CHRO) Competitors $1.12 -0.02 (-1.32%) As of 10:32 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock CHRO vs. RVPH, RNXT, AKTX, IRD, LTRN, XFOR, SCLX, OSTX, NRXP, and SRZNShould you be buying Chromocell Therapeutics stock or one of its competitors? The main competitors of Chromocell Therapeutics include Reviva Pharmaceuticals (RVPH), RenovoRx (RNXT), Akari Therapeutics (AKTX), Opus Genetics (IRD), Lantern Pharma (LTRN), X4 Pharmaceuticals (XFOR), Scilex (SCLX), OS Therapies (OSTX), NRx Pharmaceuticals (NRXP), and Surrozen (SRZN). These companies are all part of the "pharmaceutical products" industry. Chromocell Therapeutics vs. Reviva Pharmaceuticals RenovoRx Akari Therapeutics Opus Genetics Lantern Pharma X4 Pharmaceuticals Scilex OS Therapies NRx Pharmaceuticals Surrozen Chromocell Therapeutics (NYSE:CHRO) and Reviva Pharmaceuticals (NASDAQ:RVPH) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings, valuation, community ranking and media sentiment. Does the MarketBeat Community favor CHRO or RVPH? Reviva Pharmaceuticals received 28 more outperform votes than Chromocell Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Chromocell Therapeutics an outperform vote while only 90.63% of users gave Reviva Pharmaceuticals an outperform vote. CompanyUnderperformOutperformChromocell TherapeuticsOutperform Votes1100.00% Underperform VotesNo VotesReviva PharmaceuticalsOutperform Votes2990.63% Underperform Votes39.38% Do analysts prefer CHRO or RVPH? Reviva Pharmaceuticals has a consensus price target of $10.00, suggesting a potential upside of 1,023.60%. Given Reviva Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Reviva Pharmaceuticals is more favorable than Chromocell Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Chromocell Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Reviva Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29 Do institutionals and insiders believe in CHRO or RVPH? 78.0% of Chromocell Therapeutics shares are held by institutional investors. Comparatively, 63.2% of Reviva Pharmaceuticals shares are held by institutional investors. 16.4% of Chromocell Therapeutics shares are held by insiders. Comparatively, 27.2% of Reviva Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has more risk and volatility, CHRO or RVPH? Chromocell Therapeutics has a beta of 4.41, meaning that its stock price is 341% more volatile than the S&P 500. Comparatively, Reviva Pharmaceuticals has a beta of 0.05, meaning that its stock price is 95% less volatile than the S&P 500. Is CHRO or RVPH more profitable? Company Net Margins Return on Equity Return on Assets Chromocell TherapeuticsN/A N/A -453.90% Reviva Pharmaceuticals N/A N/A -252.53% Which has higher valuation & earnings, CHRO or RVPH? Reviva Pharmaceuticals is trading at a lower price-to-earnings ratio than Chromocell Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioChromocell TherapeuticsN/AN/A-$7.38M-$1.47-0.77Reviva PharmaceuticalsN/AN/A-$39.26M-$0.91-0.98 Does the media refer more to CHRO or RVPH? In the previous week, Reviva Pharmaceuticals had 4 more articles in the media than Chromocell Therapeutics. MarketBeat recorded 4 mentions for Reviva Pharmaceuticals and 0 mentions for Chromocell Therapeutics. Reviva Pharmaceuticals' average media sentiment score of 0.15 beat Chromocell Therapeutics' score of 0.00 indicating that Reviva Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Chromocell Therapeutics Neutral Reviva Pharmaceuticals Neutral SummaryReviva Pharmaceuticals beats Chromocell Therapeutics on 10 of the 15 factors compared between the two stocks. Get Chromocell Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CHRO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CHRO vs. The Competition Export to ExcelMetricChromocell TherapeuticsBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$6.87M$2.96B$5.51B$18.97BDividend YieldN/A1.89%5.11%4.03%P/E Ratio-0.7730.1522.5532.91Price / SalesN/A494.70394.9727.66Price / CashN/A168.6838.1817.53Price / Book-0.683.166.694.48Net Income-$7.38M-$72.35M$3.22B$1.02B7 Day Performance-18.77%0.47%1.11%0.75%1 Month Performance-16.36%7.67%3.59%-2.61%1 Year Performance-36.44%-22.98%15.65%4.53% Chromocell Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CHROChromocell TherapeuticsN/A$1.13-1.3%N/A-36.3%$6.87MN/A-0.774Gap DownRVPHReviva Pharmaceuticals2.7937 of 5 stars$0.75-4.7%$10.00+1,241.2%-70.9%$34.85MN/A-0.675Short Interest ↑RNXTRenovoRx2.1661 of 5 stars$0.95-6.9%$6.00+531.6%-24.4%$34.72M$43,000.00-1.676Analyst ForecastPositive NewsAKTXAkari TherapeuticsN/A$1.28+6.2%N/A-6.5%$34.04MN/A0.009News CoverageGap UpHigh Trading VolumeIRDOpus Genetics2.1417 of 5 stars$0.74-2.5%$7.33+889.4%N/A$33.71M$10.99M-0.6814LTRNLantern Pharma2.4929 of 5 stars$3.11-9.1%$25.00+703.9%-31.0%$33.54MN/A-1.7520Upcoming EarningsNews CoveragePositive NewsGap UpXFORX4 Pharmaceuticals3.8447 of 5 stars$0.19-1.0%$2.83+1,399.9%-87.2%$32.81M$2.56M-2.1080Earnings ReportStock SplitNews CoverageSCLXScilex3.1245 of 5 stars$4.70-21.9%$455.00+9,580.9%-84.1%$32.71M$56.59M-5.6680High Trading VolumeOSTXOS Therapies1.9687 of 5 stars$1.49-2.6%$18.00+1,108.1%N/A$32.28MN/A0.00N/AGap UpNRXPNRx Pharmaceuticals2.3382 of 5 stars$1.87-3.1%$28.25+1,410.7%-17.8%$31.63MN/A-0.872Analyst ForecastNews CoveragePositive NewsSRZNSurrozen3.9132 of 5 stars$9.60-1.5%$38.50+301.0%+2.3%$31.50M$10.66M-0.4480Short Interest ↓Positive News Related Companies and Tools Related Companies Reviva Pharmaceuticals Competitors RenovoRx Competitors Akari Therapeutics Competitors Opus Genetics Competitors Lantern Pharma Competitors X4 Pharmaceuticals Competitors Scilex Competitors OS Therapies Competitors NRx Pharmaceuticals Competitors Surrozen Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CHRO) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chromocell Therapeutics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Chromocell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CHRO Stock Free CHRO Stock Alerts